Related Experiment Video

Updated: May 29, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K

Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology

Irene Sevilla-Carrillo1, Eloína García-Tercero1, Carlos Alonso-Moreno1

  • 1Departamento de Química Inorgánica, Orgánica y Bioquímica, Facultad de Farmacia-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Castilla-La Mancha, Unidad nanoDrug, Albacete, 02071, Spain.

Anti-Cancer Agents in Medicinal Chemistry
|February 4, 2025
PubMed

Insights

Antibody-drug conjugates (ADCs) represent a major advance in cancer therapy, linking antibodies to potent drugs for targeted treatment. Ongoing research aims to optimize ADC design for improved efficacy and reduced side effects.

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Antibody-drug conjugates (ADCs) integrate monoclonal antibodies with cytotoxic drugs for targeted cancer therapy.
  • ADCs leverage antibody specificity to deliver potent drugs directly to cancer cells, minimizing systemic toxicity.

Purpose of the Study:

  • To provide a comprehensive review of current Antibody-drug conjugate (ADC) technology.
  • To discuss FDA-approved ADCs, ongoing clinical trials, and emerging innovations in ADC development.
  • To highlight future research directions for optimizing ADC efficacy and safety.

Main Methods:

  • Literature review of Antibody-drug conjugate (ADC) components, mechanisms, and clinical applications.
  • Analysis of current FDA-approved ADCs and agents in clinical development.
  • Exploration of novel ADC strategies, including bispecific antibodies and pro-drug conjugates.

Main Results:

  • ADCs have emerged as a significant therapeutic class in oncology.
  • Current ADC technology encompasses approved drugs and numerous candidates in clinical trials.
  • Innovations like bispecific antibodies and pro-drug conjugates show promise for enhanced targeting and reduced toxicity.

Conclusions:

  • Further research is crucial for refining Antibody-drug conjugate (ADC) design and maximizing therapeutic potential.
  • Optimizing ADC strategies can lead to improved cancer treatment outcomes.
  • Continued innovation in ADC development is essential for overcoming challenges in targeted cancer therapy.
Keywords:
ADCsFDA-approved drugsantibodyclinical trials.mechanisms of actiononcology

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.8K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.0K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
329
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
58.8K